ADAMTS5 in Healthy Muscle and Muscular Dystrophy

Total Page:16

File Type:pdf, Size:1020Kb

ADAMTS5 in Healthy Muscle and Muscular Dystrophy ADAMTS5 in healthy muscle and muscular dystrophy Adam Thomas Piers ORCID ID – 0000-003-4914-3451 Doctor of Philosophy November 2016 Faculty of Veterinary Science The University of Melbourne This thesis is submitted in total fulfillment of the requirements of the degree. i ii Abstract A Disintegrin and Metalloproteinase with Thrombospondin motifs 5 (ADAMTS5) is an extracellular matrix (ECM) protease that has been shown to exacerbate cartilage destruction in a murine arthritis model. Its function in skeletal muscle remains relatively unknown, aside from in vitro work highlighting its importance in myoblast fusion (1), and embryonic neuromuscular development (2). Microarray analysis of adult muscle from the mdx mouse model of muscular dystrophy showed that Adamts5 gene expression was upregulated compared to wild type mice (3). Significantly, this finding was supported by work showing that ADAMTS5 protein levels were elevated in the serum of both mdx mice and Duchenne muscular dystrophy (DMD) patients (4). This study went further to demonstrate that ADAMTS5 serum levels were amenable to anti- sense oligonucleotide exon skipping treatment, thus demonstrating that ADAMTS5 may be a therapy-responsive biomarker for future pre-clinical DMD trials. The first part of this thesis investigated the role of ADAMTS5 in adult skeletal muscle by comparing wild type (WT) and Adamts5-/- knockout (KO) mice. The proteolytic cleavage of a known ADAMTS5 proteoglycan target, versican, was utilised as a readout of ADAMTS activity. Versican cleavage was detected using a neo-epitope antibody specific for the newly created C- terminal DPEAAE sequence of the cleaved versican product. It was demonstrated that versican cleavage was significantly reduced in KO muscle compared to WT muscle. The lack of upregulation in the gene expression of other known ADAMTS versicanases in KO mice demonstrated that ADAMTS5 was the major versican processing ADAMTS member in skeletal muscle. However, despite these differences in proteolytic activity, no differences were observed in postnatal muscle growth or function between WT and KO mice. Thus demonstrating that ADAMTS5 is dispensable for postnatal muscle development and function. Positive immuno-staining for ADAMTS-cleaved versican fragments at the neuromuscular junction and around endothelial cells suggested that ADAMTS proteinases may play a role in these tissues. Previous work has shown that the proteolytic processing of ECM proteins is important for angiogenesis (5), while Adamts5 has been detected in the developing murine neuromuscular junction (2). To investigate the role of ADAMTS5 in angiogenesis and neuromuscular changes, WT and KO mice were exercised. Endurance exercise induces skeletal muscle adaptations and remodelling of the ECM, including the upregulation of various ECM proteins and proteases (6-8). This thesis showed that exercise significantly upregulated the gene expression of ADAMTS5 in muscle, but not the activity as measured by DPEAAE immuno- blotting. The most significant result was that the typical exercise-induced adaptations observed in WT muscle, namely oxidative fibre type switching and angiogenesis, were inhibited in KO iii muscle. No differences were observed in the gene expression of the known oxidative pathway regulators calcineurin, PGC-1a, or VEGF-α. These results suggest that ADAMTS5 is involved in how muscle adapts to the demands of endurance exercise, possibly via ECM remodelling at the neuromuscular junction and/or endothelial cells. To investigate whether the genetic ablation of ADAMTS5 ameliorated the pathology of mdx mice, KO mice were crossed with mdx mice to create mdx wt and mdx ko littermates. The gene expression and activity of ADAMTS5 was shown to be increased in mdx wt mice compared to WT mice, which led to the hypothesis that elevated ADAMTS proteoglycan proteolysis may exacerbate the mdx pathology. Previous work has suggested that ECM cleavage products act as damage-associated molecular patterns (DAMPs) to induce pathological inflammatory responses (9, 10). The pathology of 12 week old mdx wt and mdx ko mice were compared based on measures of muscle damage and function. No differences were observed in the levels of tibialis anterior (TA) muscle necrosis, diaphragm fibrosis, or the gene expression of inflammatory factors in the TA muscles of mdx wt and mdx ko mice. No improvement was observed in the force producing capacity of mdx ko TA muscles compared to mdx wt. However, mdx ko mice did display a significant improvement in their resistance to fatigue compared to mdx wt mice. The oxidative profile of mdx wt and mdx ko mice were not different when assessed based on myosin heavy chain isoform expression and gene expression analysis of oxidative markers. Overall, these results demonstrate that the genetic ablation of ADAMTS5 is not a viable therapy for the treatment of DMD. This thesis demonstrated that fibroblasts were responsible for producing ADAMTS5 in the ECM surrounding skeletal muscle. To investigate how the genetic ablation of ADAMTS5 affected the ECM proteome (matrisome), fibroblasts were isolated from WT and KO mice and grown in tissue culture. Gene expression analysis of key ECM proteins demonstrated that KO fibroblast cultures were capable of producing a normal matrix. Proteins were then extracted from WT and KO fibroblasts using a sequential extraction protocol to allow label-free quantitative proteomic analysis to be performed. ECM protein abundance differences were evident in the amount of fibromodulin and fibrillin-1 between the groups, but no major differences were observed in the overall matrisome composition. Principal component analysis revealed variability within the WT samples, while DPEAAE immuno-blotting showed no difference in the processing of versican between WT and KO fibroblasts. These results suggest that ADAMTS5 is less active in vitro in cultured fibroblasts than in skeletal muscle. Future proteomic analysis using skeletal muscle from WT and KO mice may provide more information regarding the role of ADAMTS5 in the matrisome. iv Declaration This is to certity that: (i) the thesis comprises only my original work towards the PhD except where indicated; (ii) due acknowledgement has been made in the text to all other material used; and (iii) the thesis is fewer than 100,000 words in length, exclusive of tables, maps, bibliographies and appendices. Adam Thomas Piers v Preface All work presented in this thesis was completed during the PhD candidature of Adam Piers. The following work was performed in collaboration with others: The initial fibroblast isolation steps were performed with the help of Christopher Kintakas. Dr Constanza Angelucci provided training in sequential protein extractions and mass spectrometry sample preparation. Protein samples were run on the Orbitrap mass analyser by Dr Nicholas Williamson and Dr Ching-Seng Ang at Bio21. Training for the physiological apparatus was provided by Professor Gordon Lynch and Tim Naim at The University of Melbourne. Dr Peter Houweling aided in the setup of the physiological equipment and during some experiments. Dr Jason White kindly helped during the setup of the exercise cages and during the initial computer analysis. Finally, I am grateful to Dr Chantal Coles for training me in the dark art of Western blotting. vi Acknowledgements This has been a hugely challenging and rewarding journey, and one that I could not have undertaken without the incredible people that have been by my side here in Melbourne and across the Nullarbor. I would like to start by thanking my two supervisors Jason and Shireen. ADAMTS5 has been a hard beast for all of us to tame, but the two of you have always been there pushing me to finish. Thank you for affording me the freedom to explore my ideas, but also knowing when to reign me in when I’ve inevitably drifted off on a tangential line of enquiry. Your support has taken me across the world presenting my work and meeting some of the greatest minds in our field. I think I’m finally beginning to understand what a scientist is. To the past and present members of our lab, I also thank you for your support. I want to single out Chantal and Chris as we have formed quite the TS5 team over the past couple of years. I have loved our deep Friday chats, epic lab sessions, conference trips and of course the onion farmer shenanigans. You are both very dear friends to me and I look forward to many more adventures together out of the lab. I also want to extend my thanks to Keryn in Lebron country, Liam in Memphis, Connie in Tassie, and Pete, Alex, and Marta here in Melbourne, who were all there for me as friends and as constant sources of inspiration. Finally, I want to acknowledge the support of Boris Struk at Muscular Dystrophy Australia, who has been a vital supporter of my research. Living away from my family over the course of my PhD has been hard, but has also led to me forming the most incredible connection with my friends. In particular Willow, Tahlia, Glynn and Lauren. I have lived with all of you at different stages over the past 5 years, and I want to thank you for your immense support and warmth. Big thanks to Henrik, Akin and the TSML crew for your wise words and love. I am also deeply indebted to the Spiller family; Marisa, Bruno, Dan, and Caity, for taking me in and supporting me like a member of your family. I have always felt extremely loved and welcome in your home, and will never forget what you did for me. To my amazing family, you have given so much from afar. My trips home to the West always filled me with such love and energy, especially at the end. I will never forget my time sitting in the front room of 105 writing my chapters as I looked out on the street listening to The Boss. Thank you Mum, Dad, Hannah, Holly, Kuks, Wallace, Kaia, Bess and Bonnie for always being on the end of the phone when I needed you and for telling me that you were proud of what I was trying to accomplish.
Recommended publications
  • Expression and Preliminary Functional Analysis of Siglec-F on Mouse Macrophages*
    386 Feng et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2012 13(5):386-394 Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: [email protected] Expression and preliminary functional analysis of * Siglec-F on mouse macrophages Yin-he FENG, Hui MAO†‡ (Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China) †E-mail: [email protected] Received Aug. 4, 2011; Revision accepted Jan. 18, 2012; Crosschecked Mar. 30, 2012 Abstract: Sialic acid-binding immunoglobulin-like lectin (Siglec)-F is a mouse functional paralog of human Siglec-8 that induces apoptosis in human eosinophils, and therefore may be useful as the basis of treatments for a variety of disorders associated with eosinophil hyperactivity, such as asthma. The expression pattern and functions of this protein in various cell types remain to be elucidated. The aim of this study was to determine the expression of Siglec-F on mouse macrophages by immunocytochemical staining, and also to investigate the effects of Siglec-F engagement by a Siglec-F antibody on phagocytic activity of macrophages. The results showed that Siglec-F expression was detected on mouse alveolar macrophages, but not on peritoneal macrophages. Furthermore, Siglec-F engagement did not affect the phagocytic activity of alveolar macrophages in the resting state or in the activated state following stimulation by the proinflammatory mediator tumor necrosis factor alpha (TNF-α) or lipopolysaccharide (LPS). Siglec-F expression on alveolar macrophages may be a result of adaptation.
    [Show full text]
  • Role of Proteases in Dysfunctional Placental Vascular Remodelling in Preeclampsia
    Accepted Manuscript Role of proteases in dysfunctional placental vascular remodelling in preeclampsia Jaime A. Gutiérrez, Isabel Gómez, Delia I. Chiarello, Rocío Salsoso, Andrés D. Klein, Enrique Guzmán-Gutiérrez, Fernando Toledo, Luis Sobrevia PII: S0925-4439(19)30115-2 DOI: https://doi.org/10.1016/j.bbadis.2019.04.004 Reference: BBADIS 65448 To appear in: BBA - Molecular Basis of Disease Received date: 23 February 2018 Revised date: 20 December 2018 Accepted date: 6 January 2019 Please cite this article as: J.A. Gutiérrez, I. Gómez, D.I. Chiarello, et al., Role of proteases in dysfunctional placental vascular remodelling in preeclampsia, BBA - Molecular Basis of Disease, https://doi.org/10.1016/j.bbadis.2019.04.004 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Role of proteases in dysfunctional placental vascular remodelling in preeclampsia Jaime A. Gutiérrez1,7 *, Isabel Gómez1, Delia I Chiarello7, Rocío Salsoso5,7†, Andrés D Klein2, Enrique Guzmán-Gutiérrez3, Fernando Toledo4,7, Luis Sobrevia5,6,7 * 1 Cellular Signaling and Differentiation Laboratory (CSDL), School of Medical Technology, Health Sciences Faculty, Universidad San Sebastián, Santiago 7510157, Chile. 2 Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7590943, Chile.
    [Show full text]
  • Global Analysis Reveals the Complexity of the Human Glomerular Extracellular Matrix
    Global analysis reveals the complexity of the human glomerular extracellular matrix Rachel Lennon,1,2 Adam Byron,1,* Jonathan D. Humphries,1 Michael J. Randles,1,2 Alex Carisey,1 Stephanie Murphy,1,2 David Knight,3 Paul E. Brenchley,2 Roy Zent,4,5 and Martin J. Humphries.1 1Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, UK; 2Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK; 3Biological Mass Spectrometry Core Facility, Faculty of Life Sciences, University of Manchester, Manchester, UK; 4Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; and 5Veterans Affairs Hospital, Nashville, TN, USA. *Present address: Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. Running title: Proteome of the glomerular matrix Word count: Abstract: 208, main text 2765 Corresponding author: Dr Rachel Lennon, Wellcome Trust Centre for Cell-Matrix Research, Michael Smith Building, University of Manchester, Manchester M13 9PT, UK. Phone: 0044 (0) 161 2755498. Fax: 0044 (0) 161 2755082. Email: [email protected] Abstract The glomerulus contains unique cellular and extracellular matrix (ECM) components, which are required for intact barrier function. Studies of the cellular components have helped to build understanding of glomerular disease; however, the full composition and regulation of glomerular ECM remains poorly understood. Here, we employed mass spectrometry–based proteomics of enriched ECM extracts for a global analysis of human glomerular ECM in vivo and identified a tissue-specific proteome of 144 structural and regulatory ECM proteins. This catalogue includes all previously identified glomerular components, plus many new and abundant components.
    [Show full text]
  • And MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment
    International Journal of Molecular Sciences Review Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment Stephan Niland and Johannes A. Eble * Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, 48149 Münster, Germany; [email protected] * Correspondence: [email protected] Abstract: The tumor microenvironment (TME) has become the focus of interest in cancer research and treatment. It includes the extracellular matrix (ECM) and ECM-modifying enzymes that are secreted by cancer and neighboring cells. The ECM serves both to anchor the tumor cells embedded in it and as a means of communication between the various cellular and non-cellular components of the TME. The cells of the TME modify their surrounding cancer-characteristic ECM. This in turn provides feedback to them via cellular receptors, thereby regulating, together with cytokines and exosomes, differentiation processes as well as tumor progression and spread. Matrix remodeling is accomplished by altering the repertoire of ECM components and by biophysical changes in stiffness and tension caused by ECM-crosslinking and ECM-degrading enzymes, in particular matrix metalloproteinases (MMPs). These can degrade ECM barriers or, by partial proteolysis, release soluble ECM fragments called matrikines, which influence cells inside and outside the TME. This review examines the changes in the ECM of the TME and the interaction between cells and the ECM, with a particular focus on MMPs. Keywords: tumor microenvironment; extracellular matrix; integrins; matrix metalloproteinases; matrikines Citation: Niland, S.; Eble, J.A. Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix 1. Introduction Interactions in the Tumor Microenvironment.
    [Show full text]
  • Human ADAM12 Quantikine ELISA
    Quantikine® ELISA Human ADAM12 Immunoassay Catalog Number DAD120 For the quantitative determination of A Disintegrin And Metalloproteinase domain- containing protein 12 (ADAM12) concentrations in cell culture supernates, serum, plasma, and urine. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 PRECAUTIONS .........................................................................................................................................................................4
    [Show full text]
  • Quantikine® ELISA
    Quantikine® ELISA Human ADAMTS13 Immunoassay Catalog Number DADT130 For the quantitative determination of human A Disintegrin And Metalloproteinase with Thombospondin type 1 motif, 13 (ADAMTS13) concentrations in cell culture supernates, serum, and plasma. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................4 PRECAUTIONS .........................................................................................................................................................................4
    [Show full text]
  • Association of ADAM12 Gene Polymorphisms with Knee Osteoarthritis Susceptibility
    www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2017 Association of ADAM12 gene polymorphisms with knee osteoarthritis susceptibility SUPPLEMENTARY MATERIALS REFERENCES candidate genes for the prevalence and progression of knee osteoarthritis. Arthritis Rheum. 2004;50:2497-2507. 1. Poonpet T, Tammachote R, Tammachote N, Kanitnate S, 11. Kerna I, Kisand K, Laitinen P, Tamm A, Tamm A. Honsawek S. Association between ADAM12 polymorphism Association of metallopeptidase domain 12 (ADAM12) and knee osteoarthritis in Thai population. Knee. gene polymorphisms and ADAM12 protein with the 2016;23:357-361. development of knee osteoarthritis. Osteoarthritis Cartilage. 2. Wang L, Guo L, Tian F, Hao R, Yang T. Analysis of single 2010;18. nucleotide polymorphisms within ADAM12 and risk of 12. Stark K, Straub RH, Blažičková S, Hengstenberg C, knee osteoarthritis in a Chinese Han population. Biomed Rovenský J. Genetics in neuroendocrine immunology: Res Int. 2015;2015:518643. implications for rheumatoid arthritis and osteoarthritis. Ann 3. Lou S, Zhao Z, Qian J, Zhao K, Wang R. Association N Y Acad Sci. 2010;1193. of single nucleotide polymorphisms in ADAM12 gene 13. Limer KL, Tosh K, Bujac SR, McConnell R, Doherty S, with susceptibility to kneeosteoarthritis: a case-control Nyberg F, Zhang W, Doherty M, Muir KR, Maciewicz study in a Chinese Han population. Int J Clin Exp Pathol. RA. Attempt to replicate published genetic associations 2014;7:5154-5159. in a large, well-defined osteoarthritis case-control 4. Kerna I, Kisand K, Tamm AE, Kumm J, Tamm AO. population (the GOAL study). Osteoarthritis Cartilage. Two single-nucleotide polymorphisms in ADAM12 2009;17:782-789. gene are associated with early and late radiographic 14.
    [Show full text]
  • ADAMTS13 and 15 Are Not Regulated by the Full Length and N‑Terminal Domain Forms of TIMP‑1, ‑2, ‑3 and ‑4
    BIOMEDICAL REPORTS 4: 73-78, 2016 ADAMTS13 and 15 are not regulated by the full length and N‑terminal domain forms of TIMP‑1, ‑2, ‑3 and ‑4 CENQI GUO, ANASTASIA TSIGKOU and MENG HUEE LEE Department of Biological Sciences, Xian Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, P.R. China Received June 29, 2015; Accepted July 15, 2015 DOI: 10.3892/br.2015.535 Abstract. A disintegrin and metalloproteinase with thom- proteolysis activities associated with arthritis, morphogenesis, bospondin motifs (ADAMTS) 13 and 15 are secreted zinc angiogenesis and even ovulation [as reviewed previously (1,2)]. proteinases involved in the turnover of von Willebrand factor Also known as the VWF-cleaving protease, ADAMTS13 and cancer suppression. In the present study, ADAMTS13 is noted for its ability in cleaving and reducing the size of the and 15 were subjected to inhibition studies with the full-length ultra-large (UL) form of the VWF. Reduction in ADAMTS13 and N-terminal domain forms of tissue inhibitor of metallo- activity from either hereditary or acquired deficiency causes proteinases (TIMPs)-1 to -4. TIMPs have no ability to inhibit accumulation of UL-VWF multimers, platelet aggregation and the ADAMTS proteinases in the full-length or N-terminal arterial thrombosis that leads to fatal thrombotic thrombocy- domain form. While ADAMTS13 is also not sensitive to the topenic purpura [as reviewed previously (1,3)]. By contrast, hydroxamate inhibitors, batimastat and ilomastat, ADAMTS15 ADAMTS15 is a potential tumor suppressor. Only a limited app can be effectively inhibited by batimastat (Ki 299 nM). In number of in-depth investigations have been carried out on the conclusion, the present results indicate that TIMPs are not the enzyme; however, expression and profiling studies have shown regulators of these two ADAMTS proteinases.
    [Show full text]
  • ADAMTS Proteases in Vascular Biology
    Review MATBIO-1141; No. of pages: 8; 4C: 3, 6 ADAMTS proteases in vascular biology Juan Carlos Rodríguez-Manzaneque 1, Rubén Fernández-Rodríguez 1, Francisco Javier Rodríguez-Baena 1 and M. Luisa Iruela-Arispe 2 1 - GENYO, Centre for Genomics and Oncological Research, Pfizer, Universidad de Granada, Junta de Andalucía, 18016 Granada, Spain 2 - Department of Molecular, Cell, and Developmental Biology, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA Correspondence to Juan Carlos Rodríguez-Manzaneque and M. Luisa Iruela-Arispe: J.C Rodríguez-Manzaneque is to be contacted at: GENYO, 15 PTS Granada - Avda. de la Ilustración 114, Granada 18016, Spain; M.L. Iruela-Arispe, Department of Molecular, Cell and Developmental Biology, UCLA, 615 Charles Young Drive East, Los Angeles, CA 90095, USA. [email protected]; [email protected] http://dx.doi.org/10.1016/j.matbio.2015.02.004 Edited by W.C. Parks and S. Apte Abstract ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) proteases comprise the most recently discovered branch of the extracellular metalloenzymes. Research during the last 15 years, uncovered their association with a variety of physiological and pathological processes including blood coagulation, tissue repair, fertility, arthritis and cancer. Importantly, a frequent feature of ADAMTS enzymes relates to their effects on vascular-related phenomena, including angiogenesis. Their specific roles in vascular biology have been clarified by information on their expression profiles and substrate specificity. Through their catalytic activity, ADAMTS proteases modify rather than degrade extracellular proteins. They predominantly target proteoglycans and glycoproteins abundant in the basement membrane, therefore their broad contributions to the vasculature should not come as a surprise.
    [Show full text]
  • Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1)
    Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1) Bayarri-Olmos, Rafael; Kirketerp-Moller, Nikolaj; Pérez-Alós, Laura; Skjodt, Karsten; Skjoedt, Mikkel Ole; Garred, Peter Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2018.02238 Publication date: 2018 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Bayarri-Olmos, R., Kirketerp-Moller, N., Pérez-Alós, L., Skjodt, K., Skjoedt, M. O., & Garred, P. (2018). Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1). Frontiers in Immunology, 9, [2238]. https://doi.org/10.3389/fimmu.2018.02238 Download date: 01. Oct. 2021 ORIGINAL RESEARCH published: 28 September 2018 doi: 10.3389/fimmu.2018.02238 Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1) Rafael Bayarri-Olmos 1*, Nikolaj Kirketerp-Moller 1, Laura Pérez-Alós 1, Karsten Skjodt 2, Mikkel-Ole Skjoedt 1 and Peter Garred 1 1 Laboratory of Molecular Medicine, Department of Clinical Immunology, Faculty of Health and Medical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 2 Department of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark Collectin-11 (CL-11) is a pattern recognition molecule of the lectin pathway of complement with diverse functions spanning from host defense to embryonic development. CL-11 is found in the circulation in heterocomplexes with the homologous collectin-10 (CL-10). Abnormal CL-11 plasma levels are associated with the presence Edited by: of disseminated intravascular coagulation, urinary schistosomiasis, and congenital Maciej Cedzynski, disorders.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Secreted Metalloproteinase ADAMTS-3 Inactivates Reelin
    The Journal of Neuroscience, March 22, 2017 • 37(12):3181–3191 • 3181 Cellular/Molecular Secreted Metalloproteinase ADAMTS-3 Inactivates Reelin Himari Ogino,1* Arisa Hisanaga,1* XTakao Kohno,1 Yuta Kondo,1 Kyoko Okumura,1 Takana Kamei,1 Tempei Sato,2 Hiroshi Asahara,2 Hitomi Tsuiji,1 Masaki Fukata,3 and Mitsuharu Hattori1 1Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 467-8603, Japan, 2Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan, and 3Division of Membrane Physiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki, Aichi 444-8787, Japan The secreted glycoprotein Reelin regulates embryonic brain development and adult brain functions. It has been suggested that reduced Reelin activity contributes to the pathogenesis of several neuropsychiatric and neurodegenerative disorders, such as schizophrenia and Alzheimer’s disease; however, noninvasive methods that can upregulate Reelin activity in vivo have yet to be developed. We previously found that the proteolytic cleavage of Reelin within Reelin repeat 3 (N-t site) abolishes Reelin activity in vitro, but it remains controversial as to whether this effect occurs in vivo. Here we partially purified the enzyme that mediates the N-t cleavage of Reelin from the culture supernatant of cerebral cortical neurons. This enzyme was identified as a disintegrin and metalloproteinase with thrombospondin motifs-3 (ADAMTS-3). Recombinant ADAMTS-3 cleaved Reelin at the N-t site. ADAMTS-3 was expressed in excitatory neurons in the cerebral cortex and hippocampus.
    [Show full text]